Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends
Metabolomics is emerging as a powerful systems biology approach for improving preclinical drug safety assessment. This review discusses current applications and future trends of metabolomics in toxicology and drug development. Metabolomics can elucidate adverse outcome pathways by detecting endogeno...
Main Authors: | Fenna Sillé, Thomas Hartung |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-01-01
|
Series: | Metabolites |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-1989/14/2/98 |
Similar Items
-
A Clinically Relevant Dosage of Mitoxantrone Disrupts the Glutathione and Lipid Metabolic Pathways of the CD-1 Mice Brain: A Metabolomics Study
by: Ana Dias-Carvalho, et al.
Published: (2023-08-01) -
Putative adverse outcome pathways for silver nanoparticle toxicity on mammalian male reproductive system: a literature review
by: Ozge Kose, et al.
Published: (2023-01-01) -
Retinaldehyde Dehydrogenase Inhibition-Related Adverse Outcome Pathway: Potential Risk of Retinoic Acid Synthesis Inhibition during Embryogenesis
by: Kichul Cho, et al.
Published: (2021-10-01) -
Monitoring of drug safety
by: B. K. Romanov, et al.
Published: (2022-06-01) -
Enhancing developmental and reproductive toxicity knowledge: A new AOP stemming from glutathione depletion
by: Alun Myden, et al.
Published: (2023-01-01)